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There are few data concerning changes in lung function and respiratory symptoms in smokers
with chronic obstructive pulmonary disease (COPD) weeks to months after quitting smoking.
We examined serial changes in spirometry and Clinical COPD Questionnaire (CCQ) scores
(measuring respiratory symptoms and health-related quality of life) in COPD participants by
smoking status during a smoking cessation trial.
In this randomized, double-blind trial, smokers with mild-to-moderate COPD were treated
with varenicline 1 mg b.i.d. or placebo for 12 weeks and followed to Week 52. Primary
endpoints of abstinence were previously reported. Secondary endpoints were mean changes
from baseline in post-bronchodilator forced expired volume in 1 s (FEV1) and CCQ scores.
Change from baseline in post-bronchodilator FEV1 was significantly improved in continuous
abstainers (121.8 mL) vs. continuous smokers (37.9 mL) at Week 12 (P Z 0.0069), but not at
Weeks 24 or 52. Mean change from baseline at Week 12 in CCQ Total Score was significantly
better in continuous abstainers (1.04) vs. continuous smokers (0.53; P < 0.0001): this
improvement was sustained at Weeks 24 and 52.
In a 1-year cessation trial of smokers with COPD, continuous abstinence compared with contin-
uous smoking significantly improved post-bronchodilator FEV1 atWeek 12 (although the difference
narrowedsubsequently) andCCQTotal ScoresatWeek12,with sustained improvement thereafter.
(Trial registry: http://www.clinicaltrials.gov; trial identifier: NCT00285012)
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Lung function in COPD after smoking cessation 1683Introduction received varenicline 1 mg b.i.d. or placebo for 12 weeksSmoking cessation is the most important strategy for reducing
the accelerated rate of decline in lung function1e3 and for
improving respiratory symptoms in smokers with chronic
obstructive pulmonary disease (COPD).4 In the Lung Health
Study, as well as slowing age-related decline in forced expired
volume in 1 s (FEV1), smoking cessation was also associated
with an absolute improvement in FEV1 among sustained quit-
ters (participants who were biochemically validated as absti-
nent at every annual visit) 1 year after enrolment.2,3 However,
there is little information concerning the time course of
improvement in lung function or in respiratory symptoms and
health-related quality of life (QoL) among COPD patients at
earlier time points in the year following smoking cessation.
Such information could be useful for informing smokers with
COPD regarding how soon the benefits of smoking cessation
could be expected after successful quitting.
Since the Lung Health Study demonstrated a significant
improvement in lung function and respiratory symptoms in
sustained quitters assessed beginning no earlier than 1 year
after study entry,2e4 we examined spirometric indices, as
well as respiratory symptoms and health-related QoL, in
association with smoking and abstinence at earlier times
during the 1-year study period of a randomized, placebo-
controlled clinical trial of vareniclineda pharmacotherapy
for smoking cessationdin 504 smokers with spirometrically-
confirmed mild-to-moderate COPD.5 Spirometry was
administered at baseline and at 12, 24 and 52 weeks
following randomization, and a respiratory QoL question-
naire was administered at baseline and regularly during the
treatment and follow-up periods. This provided an oppor-
tunity to determine the effects of sustained abstinence
from smoking on lung function, respiratory symptoms and
health status at various times over a 1-year interval
following smoking cessation in patients with COPD.
Materials and methods
Participants
Participants were smokers (10 cigarettes per day) moti-
vated to quit, with mild-to-moderate COPD (post-broncho-
dilator FEV1/forced vital capacity [FVC] <70% and FEV1%
predicted 50%). Participants who used systemic cortico-
steroids or those who had been treated or hospitalized for
a COPD exacerbation during the 4-week period prior to
screening were excluded. Other exclusion criteria have been
published previously5 and are listed in Supplemental Table 1.
The study was approved by the institutional review board at
each site, and participants provided written informed
consent. The study was conducted in compliance with the
Declaration of Helsinki6 and the International Conference on
Harmonization Good Clinical Practices Guidelines.7
Study design
The study was conducted from May 2006 to April 2009.5 This
was a randomized, double-blind, multinational, 27-centre
study in which participants with mild-to-moderate COPD(titrated during Week 1), followed by 40 weeks of non-
treatment follow-up.5 Participants were randomized to
varenicline or placebo in a 1:1 ratio using a block randomi-
zation procedure with investigative site as the stratification
variable. Investigators obtained subject randomization
numbers and treatment group assignments through a central
web-based, or telephone call-in drug management system or
through instruction from the sponsor. At the baseline visits,
eligible participants received a smoking cessation self-help
booklet and 10 min of counselling. The target quit date
(TQD) coincided with the Week 1 visit. Counselling (10 min)
was provided at clinic visits (weekly from Weeks 1e13, then
at Weeks 16, 24, 32, 40, 48 and 52) and by telephone 3 days
after the TQD and then in Weeks 14, 20, 28, 36 and 44.
Spirometry was performed before and 30e45 min after
the administration of 200 mg albuterol or salbutamol at
screening, at baseline and at Weeks 12, 24 and 52, or at
early termination visits. Spirometry was performed after
any residual bronchodilation from the last dose of COPD
medication was expected to have dissipated; participants
had been instructed not to take any COPD medication,
including inhaled bronchodilators, for the appropriate times
before the study visit. Spirometry techniques followed the
American Thoracic Society and European Respiratory
Society Task Force 2005 Guidelines.8 The spirometer was
required to print the results from at least the three best
manoeuvres (numeric results, volume-time graphs and flow-
volume graphs). Before any study participants were tested,
certification of each study site required evidence of a 3.00 L
calibration check demonstrating better than 3% spirometer
volume accuracy. The pre- and post-bronchodilator
spirometry tests from the first five participant visits were
faxed to a central reviewer (P Enright, University of Arizona,
Tucson, USA) who graded (AeF) the quality of the FEV1 and
the FVC, as was carried out for the Lung Health Study.9 Site
and technologist certification was awarded when at least
80% of the quality grades were A or B. Whenever possible,
the same spirometry technologist tested each participant
for the duration of the study. A central review of the quality
of the 10 most recent spirometry tests was initiated in June
2008 (around the time of final visits).
At each clinic visit throughout the study, participants
completed the Clinical COPD Questionnaire (CCQ; ª2003 Van
der Molen et al.),10 a 10-question instrument using a 6-point
Likert scale to assess the symptoms and health status of
patients with COPD over the past week.10 Items on the CCQ
are divided into the following domains: Respiratory Symp-
toms (e.g. shortness of breath, cough and phlegm produc-
tion [4 questions]), Functional State (e.g. ability to climb
stairs, carry out housework, dress/wash self or visit friends
etc. [4 questions]) and Mental State (level of concern about
getting a cold or feeling down due to breathing problems
[2 questions]) related to their COPD. TheTotal Score (average
of the 10 questions above) can be used to assess the effect
of the disease on the QoL of the individual.Efficacy and safety evaluations
The primary endpoint of the trial was carbon monoxide
(CO)-confirmed continuous abstinence rate (CAR) for Weeks
1684 D.P. Tashkin et al.9e12 (last 4 weeks of treatment) and the key secondary
endpoint was CAR for Weeks 9e52. Adverse events (AEs)
were recorded and followed up until resolution or stabili-
zation occurred to a level acceptable to the investigator
and sponsor. Other secondary endpoints, reported herein,
were change from baseline in post- and pre-bronchodilator
FEV1 and in the total score, as well as the individual domain
scores, for the CCQ at Weeks 12, 24 and 52.Statistical analysis
The sample size for the study of 500 randomized partici-
pants was estimated to provide at least 99% power to
detect a difference in Week 9e12 CAR between theFigure 1 Participant disposition. Reprovarenicline and placebo groups based on an odds ratio (OR)
of 2.79 and a placebo rate of 18%.5 This sample size was
estimated to also provide at least 81% power to detect
a difference in Week 9e52 CAR based on an OR of 2.21 and
a placebo rate of 9%.5
Post hoc subgroup analyses were performed with respect
to observed smoking status pattern at three time periods:
Weeks 9e12, 9e24 and 9e52. Since smoking status was
based on post-baseline data collected during active treat-
ment, the loss of randomization imposed limitations on the
interpretability of comparative smoking status results. At
each visit, abstinence was defined as a CO-confirmed
response of “no smoking since last visit”. A subject was
considered to be a continuous abstainer (or a continuous
smoker) if, for every visit in the respective time period, heduced with permission from Ref. [5].
Figure 2 Changes from baseline in post-bronchodilator
forced expired volume in 1 s (FEV1) at Weeks 12, 24 and 52
(least-squares means with adjusted 95% confidence intervals)
by smoking status (continuous abstinence vs. continuous
smoking during Weeks 9e12, 9e24 and 9e52, respectively).
*Indicates P < 0.05 for difference between continuous absti-
nence vs. continuous smoking.
Lung function in COPD after smoking cessation 1685or she was deemed abstinent (or not abstinent, respec-
tively). Participants not meeting either criterion were not
included in the subgroup analysis for that time period.
Changes from baseline in post- and pre-bronchodilator
FEV1 were analyzed via an analysis of covariance (ANCOVA)
model consisting of baseline FEV1, with smoking status,
pooled centre and their interaction, conducted separately
for each of the three time periods. Least-squares (LS)
means were presented by smoking status, with associated
individual 95% confidence intervals (CIs), adjusted to aid
the correct interpretation of overlapping intervals.11
The CCQ was analyzed with respect to Total Score as
well as separately for each of the three domains (Respira-
tory Symptoms, Functional State and Mental State). Change
from baseline in CCQ score was analyzed via an ANCOVA
model consisting of baseline CCQ score, with smoking
status, pooled centre and their interaction, conducted
separately for each of the three time periods with graphical
presentation of LS means summaries.Results
Full results for patient disposition, baseline smoking char-
acteristics, CARs and AEs have been reported previously5
and here we report a summary of those findings.Table 1 Changes from baseline in post-bronchodilator forced
squares means with adjusted 95% CIs) by smoking status (contin
9e24 and 9e52, respectively).
Continuous Abstinencea
n LS Mean Adjusted 95% CI
Week 12 120 121.8 85.0, 158.5
Week 24 76 58.4 5.7, 111.0
Week 52 60 9.6 73.4, 54.1
a Based on Weeks 9e12 for Week 12 results, Weeks 9e24 for Week
b Model included baseline FEV1, pooled centre, smoking status an
comparing the number of participants between Tables 1, 2 and 3 th
LS: least squares; CI: confidence interval; ANCOVA: analysis of covariDisposition
Briefly, 250 and 254 participants were randomized to the
varenicline and placebo treatment groups, respectively
(Fig. 1). Of these, 207 and 193, respectively, completed the
12-week treatment phase; and 176 and 157, respectively,
completed the study.5
Baseline characteristics
In summary, participants had a mean age of 57.1 years,
were mainly male (62.3%) and Caucasian (83%), smoked an
average of 40.5 pack-years and 24.4 cigarettes/day and had
a mean Fagerstro¨m Test for Nicotine Dependence score of
6.1, a mean baseline post-bronchodilator FEV1 of 69.9%
predicted and Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage I (21.9%), II (66.8%) and III (11.2%)
severity; GOLD stage III participants were randomized and
studied in violation of the entry criteria.5
Continuous abstinence rates
Varenicline (N Z 248) vs. placebo (N Z 251) CARs were
42.3% and 8.8%, respectively, (OR 8.40 [95% CI 4.99e14.14])
for Weeks 9e12 (P < 0.001), 25.8% and 7.2%, respectively,
(OR 4.88 [95% CI 2.75e8.65]) for Weeks 9e24 (P < 0.001)
and 18.6% and 5.6%, respectively, (OR 4.04 [95% CI
2.13e7.67]) for Weeks 9e52 (P < 0.001).5
Spirometry
Nearly all sites demonstrated good quality test sessions for
more than 8 of 10 final visits. The LS mean change from
baseline in post-bronchodilator FEV1 was significantly
improved (PZ 0.0069) in the continuous abstainers of Weeks
9e12 (121.8 mL) vs. continuous smokers of Weeks 9e12
(37.9 mL) (Fig. 2; Table 1). However, statistical significance
was not achieved for the Weeks 9e24 smoking status
comparison (PZ 0.0700) nor for Weeks 9e52 (PZ 0.4654).
TheLSmean change frombaseline in pre-bronchodilator FEV1
was not significantly different at any time point (Table 2).
Clinical COPD Questionnaire (CCQ)
The LS means of CCQ Total Score showed significantly
greater improvement from baseline at Week 12 in theexpired volume in 1 s (FEV1) at Weeks 12, 24 and 52 (least-
uous abstinence vs. continuous smoking during Weeks 9e12,
Continuous Smokinga ANCOVA
n LS Mean Adjusted 95% CI P valueb
252 37.9 14.0, 61.9 0.0069
165 19.1 50.3, 12.1 0.0700
155 46.3 81.3, e11.4 0.4654
24 results and Weeks 9e52 for Week 52 results.
d pooled centre by smoking status interaction. Note that when
at there are some missing values on 1 more of the measures.
ance.
Table 2 Changes from baseline in pre-bronchodilator forced expired volume in 1 s (FEV1) at Weeks 12, 24 and 52 (least-
squares means with adjusted 95% CIs) by smoking status (continuous abstinence vs. continuous smoking during Weeks 9e12,
9e24 and 9e52, respectively).
Continuous Abstinencea Continuous Smokinga ANCOVA
n LS Mean Adjusted 95% CI n LS Mean Adjusted 95% CI P valueb
Week 12 124 54.8 13.5, 96.2 261 7.0 20.1, 34.0 0.1696
Week 24 78 25.2 95.5, 45.1 179 7.4 33.4, 48.1 0.5642
Week 52 60 38.7 99.6, 22.2 156 101.8 135.2, e68.4 0.1890
a Based on Weeks 9e12 for Week 12 results, Weeks 9e24 for Week 24 results and Weeks 9e52 for Week 52 results.
b Model included baseline FEV1, pooled centre, smoking status and pooled centre by smoking status interaction. Note that when
comparing the number of participants between Tables 1, 2 and 3 that there are some missing values on 1 of the measures. LS: least
squares; CI: confidence interval; ANCOVA: analysis of covariance.
1686 D.P. Tashkin et al.continuous abstainers vs. the continuing smokers, and this
significantly greater improvement was sustained at Weeks
24 and 52 (Fig. 3A; Table 3). Furthermore, a significant
difference in improvement from baseline at Weeks 12, 24
and 52 was also observed in all three CCQ domain scores
(Respiratory Symptom score, Functional State score and
Mental State score) in the corresponding Weeks 9e12, 9e24
and 9e52 continuous abstinence subgroups as compared
with the respective continuing smoker subgroups
(Fig. 3BeD; Table 3).
Adverse events
Briefly, AEs occurred in 183 (73.8%) participants receiving
varenicline and 164 (65.3%) receiving placebo. Serious AEs
were infrequent in both groups and were not considered
treatment-related. Three participants died (two
varenicline-group participants and one placebo-group
participant); however, no deaths were considered treat-
ment-related.5 The most frequent AEs occurring in the
varenicline group were nausea (27.0% vs. 8.0%), abnormal
dreams (10.9% vs. 2.8%), upper respiratory tract infection
(9.7% vs. 8.4%), insomnia (9.7% vs. 6.0%), flatulence (7.3%
vs. 5.2%) and vomiting (6.5% vs. 2.4%).5
Discussion
Varenicline showed superior efficacy with respect to CARs
compared with placebo at the end of treatment (Weeks
9e12) and at the end of the non-treatment follow-up
period (Weeks 9e52), findings comparable to those previ-
ously obtained with varenicline in smokers in general.12,13
While a significant improvement in post-bronchodilator
FEV1 from baseline was noted at 12 weeks in continuous
abstainers vs. continuous smokers, the change in mean
post-bronchodilator FEV1 measurements diminished over
time such that the continuous abstainers had mean post-
bronchodilator FEV1 scores comparable to continuous
smokers when followed up to 1 year. The reasons for the
subsequent apparent diminution in the effect of quitting
and continuous abstinence from smoking on lung function
change that was observed at 12 weeks are unclear and
unexpected, although it should be noted that the study was
not powered to detect statistically significant differences in
lung function.These lung function findings at 1 year after quitting
smoking and remaining abstinent are in contrast to the
results of the Lung Health Study in which a statistically
significant mean increase in FEV1 (47 mL or 1.98% pre-
dicted) was noted at 1 year among the 840 participants who
were abstinent at 1 year compared with a 49 mL (0.74%
predicted) decrease in FEV1 in the continuing smokers.
3
Although spirometry was performed at 4 months among
the Special Intervention group of the Lung Health Study
(those who received intensive counselling in addition to
nicotine replacement therapy), these lung function data
have not been analyzed or reported by smoking status. In
a smoking cessation study conducted in 370 patients with
COPD (mean FEV1 55.8% predicted) using nicotine sublin-
gual tablets and behavioural support, 113 completed the
trial with 1-year follow-up, of whom 36 were successful
sustained abstainers at 1 year.14 Among sustained
abstainers, at 1 year FEV1 improved by 60 mL (P Z 0.048),
compared with a decrease of 161 mL in the 31 participants
who continued to smoke without any reduction in smoking
amount, and a decrease of 5 mL in the 46 participants who
continued to smoke but reduced their daily smoking to <7
cigarettes or by at least 50%.14 Post-baseline spirometry
data were not reported at earlier time points than 1 year
during this study. Thus, the 1-year results of the Lung
Health Study3 and a smaller study14 are at variance with the
findings from the present study. The reasons for these
differences are unclear. It is also unclear whether a greater
improvement in lung function might have occurred in the
former studies at earlier time points following successful
smoking cessation with a subsequent diminution in this
effect over the remainder of the first year after quitting, as
was found in the present study. While several studies have
shown a decrease in the age-related decline in lung func-
tion with smoking cessation over a period of 2e21 years
among smokers with chronic airflow obstruction, as
reviewed by Willemse et al.,15 to our knowledge there are
little published data on the short-term changes in lung
function over the weeks to months after quitting smoking
and remaining abstinent.
The CCQ is a validated 10-item self-administered QoL
questionnaire that measures Respiratory Symptoms, Func-
tional State and Mental State in patients with COPD.10 The
CCQ Total Score in patients with GOLD stages IeIII has
shown significant correlations with the St. George’s Respi-
ratory Questionnaire (SGRQ; rZ 0.67 to rZ 0.72), as well
Figure 3 Changes from baseline in Clinical COPD Question-
naire (CCQ) scores for the (A) Total Score and individual CCQ
domain scores of (B) Respiratory Symptoms, (C) Functional
Status and (D) Mental State at Weeks 12, 24 and 52 (least-
squares means with adjusted 95% confidence intervals) by
Lung function in COPD after smoking cessation 1687as with FEV1% predicted (r Z 0.49).10 The CCQ has also
been shown to be equally reliable and valid when compared
with the self-reported Chronic Respiratory Questionnaire
(CRQ-SR) in patients with COPD.16 In the present study,
sustained quitting was associated with improvements in
QoL in participants with mild-to-moderate COPD, as
demonstrated by the fact that the continuously abstinent
participants showed significantly greater improvements
than the continuous smokers in each of the domains of the
CCQ (Respiratory Symptoms, Functional State and Mental
State), as well as in the mean Total Score changes from
baseline (Fig. 3AeD; Table 3). The disparity between the
comparatively sustained benefits of continuous abstinence
from smoking with respect to improvement in respiratory
symptoms and QoL compared with the disappointingly
diminishing benefits observed with spirometry suggests that
the symptomatic improvement was probably related, in
large part, to factors other than improvement in spiro-
metric indices, possibly including a reduction in hyperin-
flation that was not assessed in this study.
While a number of non-randomized studies have shown
beneficial effects of smoking cessation on respiratory
symptoms in smokers in general,17 few longitudinal studies
are available regarding the effect of smoking cessation on
respiratory symptoms in smokers with COPD. The largest
such study was the Lung Health Study, in which dyspnoea,
cough 3 months/year and phlegm 3 months/year were
present in 42e44%, 49e51% and 42e43%, respectively, of
participants in the different smoking intervention groups at
baseline.4 The change in prevalence of respiratory symp-
toms from baseline was assessed annually with the first
post-baseline assessment having been performed at the
first annual visit. Most of the change in the prevalence of
symptoms occurred during the first year of follow-up: the
sustained quitters showing the greatest decline and the
continuing smokers the least decline, with little change
over the remaining 4 years of the 5-year trial. Results for
chronic cough, sputum production and shortness of breath
were very similar to one another. Unlike the present study,
however, the impact of changes in smoking habits on
respiratory symptoms was not assessed at earlier time
points than 1 year following smoking cessation. In a much
smaller smoking cessation study in COPD patients, signifi-
cant improvements in SGRQ total and domain scores from
baseline to 1 year were noted in the 36 continuous
abstainers: 10.9 (95% CI e15.5, 6.4) for Total Score;
28.6 (95% CI: 35.4, 21.7) for symptoms score; 6.3
(95% CI e12.1, 0.6) for activity score; and 8.0 (95% CI
e12.6, 3.5) for impact score.14 These results are consis-
tent with the findings from the present study of significant
improvements in QoL in continuous abstainers at 1 year.
In a randomized, controlled trial of behavioural coun-
selling for smoking cessation in participants with mild-to-
moderate COPD, mean changes in baseline total and
domain scores for the CCQ were assessed among those whosmoking status (continuous abstinence vs. continuous smoking
during Weeks 9e12, 9e24 and 9e52, respectively). *Indicates
P < 0.05 for difference between continuous abstinence vs.
continuous smoking.
Table 3 Changes from baseline in Clinical COPD Questionnaire (CCQ) scores for the Total Score and individual CCQ domain
scores (Respiratory Symptoms, Functional Status and Mental State) at Weeks 12, 24 and 52 (least-squares means with adjusted
95% CIs) by smoking status (continuous abstinence vs. continuous smoking during Weeks 9e12, 9e24 and 9e52, respectively).
CCQ Change from
Baseline to:
Continuous Abstinencea Continuous Smokinga ANCOVA
n LS Mean Adjusted 95% CI n LS Mean Adjusted 95% CI P valueb
Total Score Week 12 125 1.04 1.15, 0.93 235 0.53 0.60, 0.45 <0.0001
Week 24 80 1.16 1.29, 1.03 180 0.43 0.51, 0.35 <0.0001
Week 52 59 1.13 1.33, 0.93 152 0.25 0.35, 0.15 <0.0001
Respiratory
Symptoms
Week 12 125 1.50 1.63, 1.36 236 0.75 0.85, 0.66 <0.0001
Week 24 80 1.69 1.85, 1.54 181 0.67 0.76, 0.58 <0.0001
Week 52 60 1.59 1.81, 1.37 153 0.37 0.49, 0.24 <0.0001
Functional
Status
Week 12 125 0.60 0.71, 0.48 235 0.27 0.35, 0.19 0.0015
Week 24 80 0.68 0.83, 0.53 180 0.18 0.27, 0.09 <0.0001
Week 52 60 0.64 0.85, 0.44 152 0.08 0.19, 0.04 0.0006
Mental State Week 12 125 1.02 1.16, 0.87 236 0.57 0.66, 0.47 0.0002
Week 24 80 1.05 1.23, 0.87 181 0.45 0.56, 0.35 <0.0001
Week 52 59 1.07 1.33, 0.82 153 0.34 0.48, 0.21 0.0003
a Based on Weeks 9e12 for Week 12 results, Weeks 9e24 for Week 24 results and Weeks 9e52 for Week 52 results.
b Model included baseline response value, pooled centre, smoking status and pooled centre by smoking status interaction. Note that
when comparing the number of participants between Tables 1, 2 and 3 that there are some missing values on 1 of the measures.
LS: least squares; CI: confidence interval; ANCOVA: analysis of covariance.
1688 D.P. Tashkin et al.had prolonged abstinence from smoking at 26 weeks
(n Z 62e67, depending on domain) and those with pro-
longed abstinence at 52 weeks (n Z 28e30, depending on
domain).16 The results demonstrated statistically signifi-
cant improvements in the total and symptom scores for the
CCQ at 26 weeks that were maintained at 52 weeks, indi-
cating that the improvements in respiratory symptoms and
QoL following smoking cessation are durable.
While the mechanism for the improvements in lung
function and respiratory symptoms following smoking
cessation in patients with COPD is most likely related to at
least a partial reversal of pathological and inflammatory
changes in the lung that had been induced by smoking in
the first place, only a few studies, mostly cross-sectional,
provide information relating to possible effects of smoking
cessation on lung pathology and inflammation, as reviewed
by Willemse et al.15 The most obvious change appears to be
a reduction in goblet cell hyperplasia in central airways
(although not in peripheral airways),18 consistent with
a reduction in mucus hypersecretion and symptoms of
chronic bronchitis. From cross-sectional studies conducted
in current and ex-smokers with COPD, it does not appear
that structural changes other than goblet cell hyperplasia
reverse after smoking cessation.15 It is more likely that the
slowing of the accelerated decline in FEV1 following
smoking cessation in patients with COPD is due to a reduc-
tion of inflammation, although changes in the levels of
various inflammatory cells, their products, proinflammatory
cytokines or their soluble receptors in blood have been
variable,15 possibly related in part to confounding by
inhaled corticosteroid therapy. Cross-sectional studies
evaluating bronchial biopsies and lung tissue from smokers
and ex-smokers with COPD have shown either a decrease in
or persistence of lung inflammation after smoking
cessation,19e22 although prospective studies conducted
mainly in smokers without chronic respiratory symptoms or
airflow obstruction using sputum, bronchoalveolar lavagefluid and/or blood have more consistently shown a reduc-
tion in inflammation with smoking cessation23e26 or smoking
reduction.27
In summary, analysis of serial spirometric data from the
varenicline COPD study demonstrates significant short-term
(12-week) improvements in lung function following smoking
cessation with continuous abstinence from 9 to 12 weeks,
but these short-term improvements were not sustained at
24 or 52 weeks in those who remained continuously absti-
nent. Although the reason for this diminution of the early
improvements in lung function are unclear, it is possible that
significant long-term improvements may not be evident
until a further extended period of abstinence from smoking
in excess of 1 year has been achieved. On the other hand,
stopping smoking and maintaining abstinence resulted in an
improvement in respiratory symptoms and QoL that was not
only evident at 12 weeks but also persisted for as long as 52
weeks. The longer persistence of the benefits of sustained
smoking cessation for respiratory symptoms than for lung
function change suggests that the symptomatic improve-
ment could not be entirely attributed to spirometric
improvement. Findings from this study provide evidence of
respiratory benefits of smoking cessation in COPD patients
that can be perceived in the short-term and may therefore
be useful in motivating smokers with COPD to quit.Conflict of Interest Statements
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